REGISTER
No longer recommended for systemic use of hormones? EULAR psoriatic arthritis drug guidelines updated!
Latest Psoriatic Arthritis Guidelines Unveiled, Major Updates Revealed

In recent years, the research on psoriatic arthritis (PsA) has made significant progress. The concept of the disease, treatment goals, and drug selection are constantly evolving and updating. Therefore, the data and views on the efficacy and safety of existing drug treatments for psoriatic arthritis need to be updated in a timely manner based on the "EULAR 2019 Recommendations for the Pharmaceutical Treatment of PsA"


In April 2023, 36 international experts attended the latest consensus conference, determining the levels of evidence and grades of recommendation. The updated recommendations include 7 overall principles and 11 recommended suggestions, providing treatment strategies for drug therapy. Let's take a look at the updated key points together.


7 Overall Principles: 1 New + 3 Updated


  • 1. Update principle B: The treatment of psoriatic arthritis should aim for the best possible care and must be based on a shared decision between the patient and the rheumatology expert, taking into account efficacy, safety, patient preferences, and costs.


Key updates: Patient preferences have been added as a factor to be considered, and the importance of shared decision-making has been emphasized.


  • 2. Update principle C: The musculoskeletal manifestations of PsA patients should be mainly managed by rheumatologists; if there are obvious skin involvements, rheumatologists and dermatologists should cooperate in diagnosis and treatment.


Update points: In order to be more consistent with other points, the skin involvement was revised very slightly, from "clinically significant" to "clinically relevant".


  • 3. Update principle F: When treating patients with psoriatic arthritis, consideration should be given to non-musculoskeletal manifestations (skin, eyes, and gastrointestinal); comorbidities such as obesity, metabolic syndrome, cardiovascular disease, or depression should also be considered.


Update points: Added the term "obesity" because obesity is common in psoriatic arthritis and affects the outcome.


  • 4. New principle G: The choice of treatment regimen should take into account the safety of individual action patterns to optimize the benefit-risk situation.


11 Specific Recommendation Opinions Major Update


The new guidelines focus on non-local drug treatment (local and non-drug treatments for psoriatic arthritis are also important, but are beyond the scope of the current expert group's recommendations).


Recommendation 2 (combined/updated): Non-steroidal anti-inflammatory drugs can be used to relieve musculoskeletal signs and symptoms; local injection of glucocorticoids can be considered as an adjunctive treatment.


Update points:


The above two suggestions are for short-term use of drugs, applied to symptomatic treatment.


Systemic glucocorticoids are no longer mentioned because there is little data on systemic glucocorticoid prescriptions for psoriatic arthritis, and there are many potential safety concerns, particularly in view of the high prevalence of comorbidities and cardiovascular risk factors in PsA [1,2].


The guidelines particularly emphasize that the vast majority of patients should not be treated with NSAIDs alone (without DMARDs), and only those with very mild peripheral disease or with enthesis or axial disease may derive sufficient benefit from NSAIDs as single therapy. Even in these cases, use is recommended only for short-term treatment.


Recommendation 3 (merge/update): For patients with polyarthritis or oligoarthritis and those with poor prognostic factors [such as structural damage, elevated acute phase reactants, or involvement of fingers (dactylitis) or nails], csDMARDs should be used as soon as possible. For patients with clinically active skin involvement, methotrexate is the preferred choice.


Update points:


The first-line DMARDs should be csDMARDs (i.e., MTX, leflunomide, or sulfasalazine).


Due to EULAR recommendations to follow a treat-to-target (T2T) approach, which means to reduce disease activity by at least 50% within 3 months and reach the treatment target within 6 months, csDMARD should not be continued if these treatment targets are not met. If csDMARD treatment is ineffective, another DMARD, such as bDMARD, can be used quickly.


Guidelines suggest assessing the efficacy of csDMARDs and, according to T2T, deciding after 12 weeks whether they should be continued as monotherapy.


Recommendation 4 (split/update): For patients with peripheral arthritis who have an inadequate response to at least one csDMARD, bDMARD therapy should be initiated.


Update points:


The expert group explained that if the peripheral involvement is limited and there are no adverse prognostic factors, csDMARD can be reapplied before starting bDMARD/tsDMARD if the doctor and patient agree.


Regarding bDMARD, there is no priority order.


All bDMARDs will increase the risk of infection, and the safety of different categories of bDMARDs is well in the systematic literature review (SLR).


bDMARD and csDMARD combination therapy: In patients who have tolerated treatment, it is recommended to combine a first-line bDMARD with an already applied csDMARD, especially when the first bDMARD used is a TNFi. For other combination regimens, due to the lack of data, combination therapy is not currently recommended.


Recommendation 5 (update): For patients with peripheral arthritis who have an inadequate response to at least one bDMARD, or when bDMARDs are not tolerated, JAKi may be considered after assessing safety in the context of the individual patient.


Update points:


JAKi is typically recommended as a second-line targeted treatment (or third-line DMARD). However, for some patients, JAKi may be the first choice after csDMARD (i.e., "when bDMARD is not suitable"). This "unsuitability" may include contraindications to bDMARD, practical issues with a strong preference for oral administration, and patient preferences, including possible non-adherence to injections (according to the first overall principle). Nevertheless, patients must weigh their preferences against potential risks.


Recommendation 8 (update): For patients with clinically active axial disease who have an inadequate response to NSAIDs, consideration should be given to treatment with IL-17Ai, TNFi, IL-17 A/Fi or JAKi.


Update points:


The new guideline description of axial disease has been updated from "active axial disease" to "clinical axial disease with active axial inflammation", in line with the recently updated ASAS/EULAR axSpA recommendations.


Recommendation 9 (new): The choice of medication should take into account the non-musculoskeletal manifestations associated with psoriatic arthritis; for patients with clinically active skin disease, IL-17A or IL-17A/F or IL-23 or IL-12/23 inhibitors should be prioritized; for uveitis patients, consider anti-TNF monoclonal antibodies; for inflammatory bowel disease (IBD), consider anti-TNF monoclonal antibodies or IL-23 inhibitors or IL-12/23 inhibitors or JAKi.


Supplementary key points: to propose a sequence for choosing drugs, the suggested first consideration is the PsA subtype, then the manifestations outside of MSK (always considering safety and comorbidities).


Recommendation 11 (update): For patients with sustained remission, a gradual reduction of DMARD may be considered.


Update points:


This point has not been modified. However, with increasing data on tapering, a higher grade of recommendation is suggested [3,4]. Tapering refers to "dose reduction" rather than discontinuation, as the latter often leads to relapse of the disease.


Note:


①Some studies suggest that methotrexate may be effective for nasal polyposis, but the evidence quality is low.


②Axial disease does not use glucocorticoids.


③The goal is to achieve remission or low disease activity (especially for long-standing diseases), according to a "treat-to-target" approach.


④Prior consideration should be given to the presence of relevant skin lesions, but if accompanied by inflammatory bowel disease or uveitis, the use of TNF monoclonal antibodies or (for IBD) IL-23i or 12/23i or JAKi is recommended.


⑤Improvement means a reduction of at least 50% in disease activity.


⑥Arthritis: TNFi or IL-17i or IL-12/23i or IL-23p19i; Skin: IL-17i or IL-12/23i or IL-23p19i; Uveitis: anti-TNF monoclonal antibody; IBD: anti-TNF monoclonal antibody or IL-12/23i or IL-23p19i or JAK; If bDMARD and JAKi are not suitable, mild patients can consider using PDE4i.


⑦For JAK inhibitors, caution is required for patients aged 65 years and older, current or past long-term smokers, those with a history of atherosclerotic cardiovascular disease or other cardiovascular risk factors or other risk factors for malignant tumors; patients with known risk factors for venous thromboembolism.


⑧Consider gradual reduction during sustained relief.


⑨Including abatacept.


Summary


In summary, the updated 2023 guidelines are not only helpful for clinicians, but also for healthcare professionals and patients when discussing treatment plans, and they help to promote the delivery of optimal care. These recommendations should be updated again as new data emerges and new drugs are approved for PsA.


Reference



[1]FERGUSON L D, SIEBERT S, MCINNES I B, et al. Cardiometabolic comorbidities in RA andPsA: lessons learned and future directions [J]. Nature reviews Rheumatology, 2019, 15(8): 461-74.VINCKEN N L A, BALAK D M W, KNULST A C, et al. Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review [J]. Rheumatology, 2022, 61(11): 4232-44.
[3]YE W, TUCKER L J, COATES L C. Tapering and Discontinuation of Biologics in Patients with Psoriatic Arthritis with Low Disease Activity [J]. Drugs, 2018, 78(16): 1705-15.
[4]COATES L C, PILLAI S G, TAHIR H, et al. Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-Blind Withdrawal Study [J]. 2021, 73(9): 1663-72.


0
0
Loading